ENOBライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (5 8月 2023 @ 04:58):

Stats
本日の出来高	87 289.00
平均出来高	254 603
時価総額	45.38M
EPS	$-698 421 ( 2023-08-11 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.344
ATR14	$0.193 (7.42%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-23	Miller Avram	Buy	1 000 000	Common Stock
2023-10-23	Miller Avram	Buy	27 147	Option to purchase shares of common stock
2023-10-11	Miller Avram	Buy	0
2023-10-04	Hendriks Ruud	Buy	16 129	Option to purchase shares of common stock
2023-10-04	Boeren Leni	Buy	16 129	Option to purchase shares of common stock

INSIDER POWER
95.39
Last 80 transactions
Buy: 35 900 381 \| Sell: 26 846 213

ボリューム相関

長: 0.11 (neutral)

短: -0.07 (neutral)

Signal:(77.816) Neutral

Enochian Biosciences Inc 相関

10 最も正の相関
UK	0.894
GAINL	0.893
MRACW	0.892
AYLA	0.891
KBSF	0.887
GRNV	0.885
ISNS	0.884
BIOL	0.879
VIH	0.874
OPTN	0.866

10 最も負の相関
BOCH	-0.92
ALPN	-0.918
SGH	-0.904
NXGL	-0.903
ELTK	-0.902
AMAT	-0.892
MOTNU	-0.889
STRR	-0.885
PEBK	-0.885
PLAB	-0.883

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Enochian Biosciences Inc 相関 - 通貨/商品

0.73
( moderate )

0.67
( moderate )

0.00
( neutral )

0.75
( moderate )

0.52
( weak )

-0.66
( moderate negative )

Enochian Biosciences Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-705 302

FY	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-705 302

FY	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$0

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-2.16

Financial Reports:

No articles found.

Enochian Biosciences Inc

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.